Physician profile
Erin Colleen Cooney
NPI 1679831093
$43,565.99
in general payments reported to CMS, 2019-2025
9 companies · $13K in 2025
The $13K reported for 2025 was more than what 86% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $125 · 2021: $2,925 · 2022: $7,101 · 2023: $11K · 2024: $8,851 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $11K · Travel and Lodging: $4,349 · Food and Beverage: $1,499 · Education: $35.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,004.00 |
| Consulting Fee | $11,378.40 |
| Travel and Lodging | $4,348.70 |
| Food and Beverage | $1,498.96 |
| Education | $35.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $35,955.09 | 2019-2025 | Palynziq, Voxzogo 1.2mg |
| Horizon Therapeutics Plc | $6,889.46 | 2022-2023 | Ravicti |
| Genzyme Corporation | $343.89 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $121.80 | 2023 | |
| Novartis Pharmaceuticals Corporation | $101.78 | 2024-2025 | |
| Sarepta Therapeutics, INC. | $75.61 | 2024-2025 | Elevidys |
| Ptc Therapeutics, INC. | $35.07 | 2025 | Sephience |
| Shire North American Group INC | $24.15 | 2019 | |
| Pharming Healthcare, INC. | $19.14 | 2024 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Cooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.